Wei-Ping Chou

· Horn player

Johns Hopkins University · Music Education

Active 1988–2026

h-index51

Citations13.1k

Papers350107 last 5y

Funding—

Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.

Faculty page

See your match with Wei-Ping Chou — sign in to PhdFit.Sign in

About

Wei-Ping Chou has been praised by The New York Times for her consistent, strong, and smooth, full horn playing. She was the first and only horn player in Juilliard School history to be awarded the Artist Diploma. A native of Taoyuan, Taiwan, she began playing the horn at the age of 9 and continued her studies at the Idyllwild Arts Academy under Kurt Snyder. She received her bachelor's degree from the Manhattan School of Music as a student of Jerome Ashby, and her Master of Music degree from the Juilliard School under the tutelage of Julie Landsman. Prior to her return to New York in 2011, she was acting assistant principal horn for the San Diego Symphony from 2007 to 2011. As an active freelancer in New York City, she performed regularly with orchestras and chamber groups, such as the Orchestra of St. Luke's, American Symphony Orchestra, The Knights, Wind Soloists of New York, The Metropolis Ensemble, The Decoda Ensemble, and Genghis Barbie. She can be heard in their newest album, Amp It Up. As a chamber musician, she spent many of her summers at the Marlboro Music Festival and performs on Musicians from Marlboro tours. Chou currently holds the second horn position with the Kennedy Center Opera House Orchestra/Washington National Opera Orchestra.

Research topics

Medicine
Internal medicine
Oncology
Biology
Cancer research

Selected publications

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy
Blood · 2022-08-02 · 125 citations
articleOpen access
Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive chemotherapy are disappointing. This multicenter, open-label, phase 3 trial randomized (2:1) untreated adults with FLT3mut+ AML ineligible for intensive induction chemotherapy to receive gilteritinib (120 mg/d orally) and azacitidine (GIL + AZA) or azacitidine (AZA) alone. The primary end point was overall survival (OS). At the interim ana…
Publisher OA PDF DOI
Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
Annals of Hematology · 2020-01-21 · 73 citations
article
Publisher DOI
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
Blood Advances · 2021-05-17 · 49 citations
articleOpen access
Next-generation sequencing (NGS) has been applied to measurable/minimal residual disease (MRD) monitoring after induction chemotherapy in patients with acute myeloid leukemia (AML), but the optimal time point for the test remains unclear. In this study, we aimed to investigate the clinical significance of NGS MRD at 2 different time points. We performed targeted NGS of 54 genes in bone marrow cells serially obtained at diagnosis, first complete remission (first time point), and after the first c…
Publisher OA PDF DOI
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
Journal of Clinical Oncology · 2026-03-27
articleOpen access
PURPOSE Chronic myelomonocytic leukemia (CMML) is a rare myeloid neoplasm characterized by clinical heterogeneity and is associated with poor outcomes. To date, limited molecular information has been incorporated into disease classification and risk stratification. We aimed to integrate genomic features into the clinical decision-making process for CMML. PATIENTS AND METHODS We analyzed a retrospective cohort of 3013 patients with CMML (training set) and a prospective population of 516 patients…
Publisher DOI

Frequent coauthors

Hwei‐Fang Tien
National Taiwan University Hospital
250 shared
Hsin‐An Hou
National Taiwan University Hospital
216 shared
Jih‐Luh Tang
National Taiwan University Hospital
137 shared
Chien‐Chin Lin
National Taiwan University Hospital
110 shared
Ming Yao
107 shared
Cheng‐Hong Tsai
National Taiwan University Hospital
102 shared
Yuan‐Yeh Kuo
National Taiwan University
82 shared
Bor‐Sheng Ko
National Taiwan University Hospital
79 shared

Education

Ph.D., Human Genetics Program
Johns Hopkins University

Similar researchers at Johns Hopkins University

Resume-aware match score
Save to shortlist
AI-drafted outreach

See your match with Wei-Ping Chou

PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.

Free to start
No credit card
30-second signup